Tyra Biosciences
Developer of oral FGFR-targeted medicines for urothelial cancers and achondroplasia.
$24.94
After-hours close−0.05 (−0.22%)
At close$25.00(−4.34%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.69 | — | — |
| Aug 2026 | −$0.65 | −$0.69 | −6.2% |
| May 2026 | −$0.60 | −$0.64 | −6.7% |
| Mar 2026 | −$0.54 | −$0.57 | −5.6% |
| Nov 2025 | −$0.50 | −$0.50 | 0.0% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.69 | — | — | — | — | — |
| Aug 4, 2026 | −$0.65 | −$0.69 | −6.2% | — | — | — |
| May 13, 2026 | −$0.60 | −$0.64 | −6.7% | — | — | — |
| Mar 2, 2026 | −$0.54 | −$0.57 | −5.6% | — | — | — |
| Nov 5, 2025 | −$0.50 | −$0.50 | 0.0% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 14, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 7, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 19, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 4, 2023 | ||||||
| Mar 22, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 5, 2022 | ||||||
| Mar 3, 2022 | ||||||
| Nov 3, 2021 | ||||||
| Sep 15, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||